Targeted therapies for patients with advanced NSCLC harboring wild-type EGFR : what’s new and what’s enough

摘要: Historically, non-small cell lung cancer (NSCLC) is divided into squamous and nonsquamous subtypes based on histologic features. With a growing number of oncogenic drivers being identified in NSCLC, this malignancy has been recently several distinct according to the specific molecular alterations. This new paradigm substantially highlighted treatment advanced shifting it from standard chemotherapy targeted therapy drivers. The application epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) NSCLC patients harboring activating EGFR mutations representative model precise medicine NSCLC. As role EGFR-TKIs routine management with well established, review provides an overview alternative including for wild-type as other agents either clinical available or early- late-stage development.